

Table 14.3.1.37.3.1
Summary of Dyspnoea up to 7 Days After Each Injection
Safety Set

After First Injection

	Placebo (N = 15162)	mRNA-1273 (N = 15184)
Number of Subjects Reporting Dyspnoea, n (%)	5 (<0.1)	5 (<0.1)
Number of Events	5	5
Onset Day		
Median	4.0	4.0
Min, Max	1, 6	1, 6
Duration		
Median	2.0	5.0
Min, Max	1, 13	1, 147

Dyspnoea includes adverse events with preferred term of "Dyspnoea". "Dyspnoea" is the spelling in British English.
MedDRA version 23.0.

Program Path: ¥¥wilbtia¥wilbtia01¥Moderna MODMRNA1273P301_U¥BLAYTLF¥t140301370301.sas 20DEC2021 16:46

Table 14.3.1.37.3.1
Summary of Dyspnoea up to 7 Days After Each Injection
Safety Set

After Second Injection

	Placebo (N = 14631)	mRNA-1273 (N = 14731)
Number of Subjects Reporting Dyspnoea, n (%)	7 (<0.1)	9 (<0.1)
Number of Events	7	10
Onset Day		
Median	3.0	1.0
Min, Max	1, 7	1, 4
Duration		
Median	3.0	2.0
Min, Max	1, 29	1, 17

Dyspnoea includes adverse events with preferred term of "Dyspnoea". "Dyspnoea" is the spelling in British English.
MedDRA version 23.0.

Program Path: ¥¥wilbtia¥wilbtia01¥Moderna MODMRNA1273P301_U¥BLAYTLF¥t140301370301.sas 20DEC2021 16:46